SCHEMBL13340952

SCHEMBL13340952

COc1ccc2cc([C@H](C)C(=O)C(C)(C)C(C)C)ccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.66
AKR1C3 P42330 3/20 0.66
AKR1C2 P52895 3/20 0.66
PTGS1 P23219 2/20 0.66
TSHR P16473 2/20 0.66
CDC42 P60953 1/20 0.66
RAC1 P63000 1/20 0.66
CYP1A2 P05177 1/20 0.66
SLC22A6 Q4U2R8 1/20 0.66
LMNA P02545 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C9 P11712 1/20 0.62
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALOX5 P09917 2/20 0.55
OPRM1 P35372 1/20 0.52
OPRD1 P41143 1/20 0.52
ABCB11 O95342 1/20 0.51
RIOK2 Q9BVS4 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22217506 0.88 PTGS2 (0.69) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL20887115 0.88 PTGS2 (0.69) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL14817408 0.88 PTGS2 (0.69) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL16812505 0.82 TDP1 (0.69) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL12327361 0.82 PTGS2 (0.61) PTGS2AKR1C3AKR1C2PTGS1TSHR
Naproxen SCHEMBL42434 0.80 AKR1C3 (1.00) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL5534049 0.80 PTGS2 (0.81) PTGS2AKR1C3AKR1C2PTGS1TSHR
Naproxen SCHEMBL616149 0.80 AKR1C3 (1.00) PTGS2AKR1C3AKR1C2PTGS1TSHR
SCHEMBL20887114 0.80 PTGS2 (0.81) PTGS2AKR1C3AKR1C2PTGS1TSHR
Naproxen SCHEMBL215236 0.80 AKR1C3 (1.00) PTGS2AKR1C3AKR1C2PTGS1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723509-B2 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs ALNYLAM PHARMACEUTICALS (US) 2010-05-25 US disclosed